Congenital disorder of glycosylation
MONDO:0015286Congenital disorder of glycosylation (CDG) is a fast growing group of inborn errors of metabolism characterized by defective activity of enzymes that participate in glycosylation (modification of proteins and other macromolecules by adding and processing of oligosaccharide side chains). CDG is comprised of phenotypically diverse disorders affecting multiple systems including the central nervous system, muscle function, immunity, endocrine system, and coagulation. The numerous entities in this group are subdivided, based on the synthetic pathway affected, into disorder of protein N-glycosylation, disorder of protein O-glycosylation, disorder of multiple glycosylation, and disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation.
Also known as: CDG, carbohydrate deficient glycoprotein syndrome, carbohydrate-deficient glycoprotein syndrome, congenital disorder of glycosylation, carbohydrate-deficient glycoprotein syndromes, congenital disorders of glycosylation
55 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for kids: drug may prevent transplant complications
Disease control Not yet recruitingThis study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood disorders who are getting a bone marrow transplant. GVHD is a serious complication where donor cells…
Phase: PHASE2 • Sponsor: Sung Won Choi • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Sugar supplement may calm seizures and stomach troubles in rare genetic disease
Disease control Not yet recruitingThis study tests whether a sugar called D-galactose (AVTX-801) can help people with SLC35A2-CDG, a rare inherited disorder that disrupts how the body adds sugar to proteins. The trial enrolls about 10 people of any age who have seizures or chronic digestive issues. Participants r…
Phase: PHASE2 • Sponsor: Eva Morava-Kozicz • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Back surgery boost: Bone-Marrow injection may repair discs
Disease control Not yet recruitingThis study tests whether adding a bone-marrow concentrate injection during routine back surgery helps the spinal disc heal better. About 90 adults with a herniated disc will get either surgery alone or surgery plus the injection. Researchers will use MRI scans and pain questionna…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug UX016 targets rare muscle disease
Disease control Not yet recruitingThis early-stage trial tests UX016, a drug designed to help people with GNE myopathy, a rare genetic muscle-weakening disease. Researchers will give the drug or a placebo to 24 adults to see if it is safe and improves muscle strength. The study is not yet recruiting.
Phase: PHASE1, PHASE2 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Sugar supplement shows promise for rare disease in new trial
Disease control Not yet recruitingThis phase 2b trial tests AVTX-801, a D-galactose supplement, in 8 adults with PGM1-CDG, a rare genetic disorder affecting sugar metabolism. Participants currently on D-galactose will receive either the study drug or a placebo to see if it reduces disease-related events like low …
Phase: PHASE2 • Sponsor: Eva Morava-Kozicz • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for rare anemias: drug may cut transfusions
Disease control Not yet recruitingThis Phase 2 trial tests the drug luspatercept (Reblozyl) in 45 people with rare inherited anemias that affect red blood cells. The goal is to see if it can reduce the need for blood transfusions in those who depend on them, or raise hemoglobin levels in those who don't. Particip…
Phase: PHASE2 • Sponsor: EuroBloodNet Association • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
AI could help spot rare metabolic diseases in newborns
Diagnosis Not yet recruitingThis trial will test an artificial intelligence system designed to interpret routine newborn screening tests for inherited metabolic disorders. Researchers will compare the AI's accuracy to standard manual review by trained staff. The study plans to include 200,000 newborns in Ch…
Phase: NA • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
Large survey aims to uncover hidden pain in restless legs syndrome
Knowledge-focused Not yet recruitingThis study surveys 1,000 adults with Restless Legs Syndrome (RLS) to find out how often pain is part of their symptoms and how it affects their daily lives. Participants fill out an online questionnaire about their medical history, sleep, pain, and quality of life. The goal is to…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive diabetes registry aims to unlock secrets of metabolic disease
Knowledge-focused Not yet recruitingThis 10-year observational study will follow 10,000 adults with diabetes, metabolic disorders, and related conditions like high blood pressure and fatty liver disease. Researchers will collect routine medical data to identify markers of disease severity and activity. The goal is …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC